Spire Wealth Management Buys New Stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Spire Wealth Management purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,097 shares of the company’s stock, valued at approximately $27,000.

Other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 192.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock worth $28,000 after buying an additional 806 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Fresenius Medical Care AG & Co. KGaA by 234.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company’s stock worth $71,000 after purchasing an additional 2,208 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 80.5% during the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock worth $102,000 after purchasing an additional 2,012 shares during the period. Versant Capital Management Inc boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 1,410.9% during the first quarter. Versant Capital Management Inc now owns 6,648 shares of the company’s stock worth $166,000 after buying an additional 6,208 shares in the last quarter. Finally, Assetmark Inc. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 196.3% in the fourth quarter. Assetmark Inc. now owns 7,210 shares of the company’s stock worth $163,000 after acquiring an additional 4,777 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS opened at $28.36 on Thursday. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $17.93 and a 52-week high of $30.46. The company has a quick ratio of 1.08, a current ratio of 1.46 and a debt-to-equity ratio of 0.40. The firm’s fifty day moving average is $27.83 and its two-hundred day moving average is $25.11.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.18% and a return on equity of 6.25%. The company had revenue of $5.54 billion for the quarter, compared to analysts’ expectations of $4.71 billion. Equities analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently announced an annual dividend, which was paid on Friday, June 6th. Shareholders of record on Friday, May 23rd were paid a dividend of $0.7871 per share. This represents a yield of 1.9%. The ex-dividend date was Friday, May 23rd. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.44. Fresenius Medical Care AG & Co. KGaA’s payout ratio is 50.89%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Truist Financial upped their price target on Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, May 12th. Wall Street Zen initiated coverage on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, May 20th. They set a “strong-buy” rating for the company. Finally, Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.